Segment Reporting

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE K – SEGMENT REPORTING

We have three reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments.

Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding intersegment profits. In 2017, we updated our presentation of segment net sales and operating income to the impact of foreign currency fluctuations, since our chief operating decision maker (CODM) reviews operating results both including and excluding the impact of foreign currency fluctuations and the following presentation more closely aligns to our consolidated financial statements. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items and litigation-related items. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below.

Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, Segment Reporting. The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year’s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change.

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:

	Three Months Ended March 31,
(in millions)	2018			2017
Net sales
MedSurg*	$	711		$	641
Rhythm and Neuro*	736			668
Cardiovascular	933			851
	$	2,379		$	2,160
Income (loss) before income taxes
MedSurg*	$	259		$	215
Rhythm and Neuro*	153			109
Cardiovascular	290			233
Operating income allocated to reportable segments	703			557
Corporate expenses, including hedging activities	(100		)	(61		)
Intangible asset impairment charges, acquisition-related, restructuring- and restructuring-related and litigation-related net credits (charges)	(54		)	11
Amortization expense	(141		)	(143		)
Operating income (loss)	407			364
Other expense, net	(84		)	(59		)
Income (loss) before income taxes	$	323		$	305

	Three Months Ended March 31,
Operating income as a percentage of segment net sales	2018		2017
MedSurg*	36.4	%	33.5	%
Rhythm and Neuro*	20.8	%	16.3	%
Cardiovascular	31.1	%	27.3	%